Chemical Biology Framework to Illuminate Proteostasis

Literature Cited

1. 1. 

   Åkerfelt M, Morimoto RI, Sistonen L 2010. Heat shock factors: integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 11:545–55
   [Google Scholar]
2. 2. 

   Walter P, Ron D. 2011. The unfolded protein response: from stress pathway to homeostatic regulation. Science 334:1081–86
   [Google Scholar]
3. 3. 

   Fiorese CJ, Schulz AM, Lin YF, Rosin N, Pellegrino MW, Haynes CM 2016. The transcription factor ATF5 mediates a mammalian mitochondrial UPR. Curr. Biol. 26:2037–43
   [Google Scholar]
4. 4. 

   Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S 1994. Conformational maturation of CFTR but not its mutant counterpart (ΔF508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 13:6076–86
   [Google Scholar]
5. 5. 

   Ron I, Horowitz M. 2005. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14:2387–98
   [Google Scholar]
6. 6. 

   Mirigian LS, Makareeva E, Mertz EL, Omari S, Roberts-Pilgrim AM et al. 2016. Osteoblast malfunction caused by cell stress response to procollagen misfolding in α2(I)-G610C mouse model of osteogenesis imperfecta. J. Bone Miner. Res. 31:1608–16
   [Google Scholar]
7. 7. 

   Wong MY, Shoulders MD. 2019. Targeting defective proteostasis in the collagenopathies. Curr. Opin. Chem. Biol. 50:80–88
   [Google Scholar]
8. 8. 

   Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM et al. 2010. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. PNAS 107:19573–78
   [Google Scholar]
9. 9. 

   Tang Z, Dai S, He Y, Doty RA, Shultz LD et al. 2015. MEK guards proteome stability and inhibits tumor-suppressive amyloidogenesis via HSF1. Cell 160:729–44
   [Google Scholar]
10. 10. 

    Calderwood SK, Gong J. 2016. Heat shock proteins promote cancer: It's a protection racket. Trends Biochem. Sci. 41:311–23
    [Google Scholar]
11. 11. 

    Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP et al. 2016. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 538:397–401
    [Google Scholar]
12. 12. 

    Chauhan D, Hideshima T, Anderson KC 2005. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu. Rev. Pharmacol. Toxicol. 45:465–76
    [Google Scholar]
13. 13. 

    Naito T, Momose F, Kawaguchi A, Nagata K 2007. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J. Virol. 81:1339–49
    [Google Scholar]
14. 14. 

    Phillips AM, Gonzalez LO, Nekongo EE, Ponomarenko AI, McHugh SM et al. 2017. Host proteostasis modulates influenza evolution. eLife 6:e28652
    [Google Scholar]
15. 15. 

    Geller R, Pechmann S, Acevedo A, Andino R, Frydman J 2018. Hsp90 shapes protein and RNA evolution to balance trade-offs between protein stability and aggregation. Nat. Commun. 9:e1781
    [Google Scholar]
16. 16. 

    Phillips AM, Doud MB, Gonzalez LO, Butty VL, Lin YS et al. 2018. Enhanced ER proteostasis and temperature differentially impact the mutational tolerance of influenza hemagglutinin. eLife 7:e38795
    [Google Scholar]
17. 17. 

    Phillips AM, Ponomarenko AI, Chen K, Ashenberg O, Miao J et al. 2018. Destabilized adaptive influenza variants critical for innate immune system escape are potentiated by host chaperones. PLOS Biol 16:e3000008
    [Google Scholar]
18. 18. 

    Heaton NS, Moshkina N, Fenouil R, Gardner TJ, Aguirre S et al. 2016. Targeting viral proteostasis limits influenza virus, HIV, and dengue virus infection. Immunity 44:46–58
    [Google Scholar]
19. 19. 

    Taguwa S, Maringer K, Li X, Bernal-Rubio D, Rauch JN et al. 2015. Defining Hsp70 subnetworks in dengue virus replication reveals key vulnerability in flavivirus infection. Cell 163:1108–23
    [Google Scholar]
20. 20. 

    DiChiara AS, Taylor RJ, Wong MY, Doan ND, Del Rosario AM, Shoulders MD 2016. Mapping and exploring the collagen-I proteostasis network. ACS Chem. Biol. 11:1408–21
    [Google Scholar]
21. 21. 

    Forrester A, De Leonibus C, Grumati P, Fasana E, Piemontese M et al. 2019. A selective ER-phagy exerts procollagen quality control via a calnexin-FAM134B complex. EMBO J 38:e99847
    [Google Scholar]
22. 22. 

    Okiyoneda T, Barrière H, Bagdány M, Rabeh WM, Du K et al. 2010. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329:805–10
    [Google Scholar]
23. 23. 

    Hosokawa N, Tremblay LO, You Z, Herscovics A, Wada I, Nagata K 2003. Enhancement of endoplasmic reticulum (ER) degradation of misfolded null Hong Kong α₁-antitrypsin by human ER mannosidase I. J. Biol. Chem. 278:26287–94
    [Google Scholar]
24. 24. 

    Brehme M, Voisine C, Rolland T, Wachi S, Soper JH et al. 2014. A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep 9:1135–50
    [Google Scholar]
25. 25. 

    Mok SA, Condello C, Freilich R, Gillies A, Arhar T et al. 2018. Mapping interactions with the chaperone network reveals factors that protect against tau aggregation. Nat. Struct. Mol. Biol. 25:384–93
    [Google Scholar]
26. 26. 

    Cox DW, Billingsley GD, Callahan JW 1986. Aggregation of plasma Z type α₁-antitrypsin suggests basic defect for the deficiency. FEBS Lett 205:255–60
    [Google Scholar]
27. 27. 

    Fregno I, Fasana E, Bergmann TJ, Raimondi A, Loi M et al. 2018. ER-to-lysosome-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport. EMBO J 37:e99259
    [Google Scholar]
28. 28. 

    Cooley CB, Ryno LM, Plate L, Morgan GJ, Hulleman JD et al. 2014. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. PNAS 111:13046–51
    [Google Scholar]
29. 29. 

    Chen JJ, Genereux JC, Suh EH, Vartabedian VF, Rius B et al. 2016. Endoplasmic reticulum proteostasis influences the oligomeric state of an amyloidogenic protein secreted from mammalian cells. Cell Chem. Biol. 23:1282–93
    [Google Scholar]
30. 30. 

    Wood RJ, Ormsby AR, Radwan M, Cox D, Sharma A et al. 2018. A biosensor-based framework to measure latent proteostasis capacity. Nat. Commun. 9:e287
    [Google Scholar]
31. 31. 

    Gupta R, Kasturi P, Bracher A, Loew C, Zheng M et al. 2011. Firefly luciferase mutants as sensors of proteome stress. Nat. Methods 8:879–84
    [Google Scholar]
32. 32. 

    Liu Y, Tan YL, Zhang X, Bhabha G, Ekiert DC et al. 2014. Small molecule probes to quantify the functional fraction of a specific protein in a cell with minimal folding equilibrium shifts. PNAS 111:4449–54
    [Google Scholar]
33. 33. 

    Apaja PM, Xu H, Lukacs GL 2010. Quality control for unfolded proteins at the plasma membrane. J. Cell Biol. 191:553–70
    [Google Scholar]
34. 34. 

    Frottin F, Schueder F, Tiwary S, Gupta R, Körner R et al. 2019. The nucleolus functions as a phase-separated protein quality control compartment. Science 365:342–47
    [Google Scholar]
35. 35. 

    Liu Y, Fares M, Dunham NP, Gao Z, Miao K et al. 2017. AgHalo: a facile fluorogenic sensor to detect drug-induced proteome stress. Angew. Chem. Int. Ed. Engl. 56:8672–76
    [Google Scholar]
36. 36. 

    Liu Y, Miao K, Li Y, Fares M, Chen S, Zhang X 2018. A HaloTag-based multicolor fluorogenic sensor visualizes and quantifies proteome stress in live cells using solvatochromic and molecular rotor-based fluorophores. Biochemistry 57:4663–74
    [Google Scholar]
37. 37. 

    Tokuriki N, Tawfik DS. 2009. Chaperonin overexpression promotes genetic variation and enzyme evolution. Nature 459:668–73
    [Google Scholar]
38. 38. 

    Rutherford SL, Lindquist S. 1998. Hsp90 as a capacitor for morphological evolution. Nature 396:336–42
    [Google Scholar]
39. 39. 

    Whitesell L, Santagata S, Mendillo ML, Lin NU, Proia DA, Lindquist S 2014. HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. PNAS 111:18297–302
    [Google Scholar]
40. 40. 

    Berman CM, Papa LJ III, Hendel SJ, Moore CL, Suen PH et al. 2018. An adaptable platform for directed evolution in human cells. J. Am. Chem. Soc. 140:18093–103
    [Google Scholar]
41. 41. 

    English JG, Olsen RHJ, Lansu K, Patel M, White K et al. 2019. VEGAS as a platform for facile directed evolution in mammalian cells. Cell 178:748–61
    [Google Scholar]
42. 42. 

    Moore CL, Papa LJ III, Shoulders MD 2018. A processive protein chimera introduces mutations across defined DNA regions in vivo. J. Am. Chem. Soc. 140:11560–64
    [Google Scholar]
43. 43. 

    Hess GT, Frésard L, Han K, Lee CH, Li A et al. 2016. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods 13:1036–42
    [Google Scholar]
44. 44. 

    Chen H, Liu S, Padula S, Lesman D, Griswold K et al. 2019. Efficient, continuous mutagenesis in human cells using a pseudo-random DNA editor. Nat. Biotechnol. 38:165–68
    [Google Scholar]
45. 45. 

    Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–21
    [Google Scholar]
46. 46. 

    Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS et al. 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–83
    [Google Scholar]
47. 47. 

    Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO et al. 2015. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517:583–88
    [Google Scholar]
48. 48. 

    Maji B, Moore CL, Zetsche B, Volz SE, Zhang F et al. 2017. Multidimensional chemical control of CRISPR-Cas9. Nat. Chem. Biol. 13:9–11
    [Google Scholar]
49. 49. 

    Maji B, Gangopadhyay SA, Lee M, Shi M, Wu P et al. 2019. A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell 177:1067–79
    [Google Scholar]
50. 50. 

    Bao Z, Jain S, Jaroenpuntaruk V, Zhao H 2017. Orthogonal genetic regulation in human cells using chemically induced CRISPR/Cas9 activators. ACS Synth. Biol. 6:686–93
    [Google Scholar]
51. 51. 

    Pellegrino MW, Nargund AM, Haynes CM 2013. Signaling the mitochondrial unfolded protein response. Biochim. Biophys. Acta Mol. Cell Res. 1833:410–16
    [Google Scholar]
52. 52. 

    Hentze N, Le Breton L, Wiesner J, Kempf G, Mayer MP 2016. Molecular mechanism of thermosensory function of human heat shock transcription factor Hsf1. eLife 5:e11576
    [Google Scholar]
53. 53. 

    Kijima T, Prince TL, Tigue ML, Yim KH, Schwartz H et al. 2018. HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation. Sci. Rep. 8:e6976
    [Google Scholar]
54. 54. 

    Ryno LM, Genereux JC, Naito T, Morimoto RI, Powers ET et al. 2014. Characterizing the altered cellular proteome induced by the stress-independent activation of heat shock factor 1. ACS Chem. Biol. 9:1273–83
    [Google Scholar]
55. 55. 

    Zheng X, Beyzavi A, Krakowiak J, Patel N, Khalil AS, Pincus D 2018. Hsf1 phosphorylation generates cell-to-cell variation in Hsp90 levels and promotes phenotypic plasticity. Cell Rep 22:3099–106
    [Google Scholar]
56. 56. 

    Zheng X, Krakowiak J, Patel N, Beyzavi A, Ezike J et al. 2016. Dynamic control of Hsf1 during heat shock by a chaperone switch and phosphorylation. eLife 5:e18638
    [Google Scholar]
57. 57. 

    Anckar J, Hietakangas V, Denessiouk K, Thiele DJ, Johnson MS, Sistonen L 2006. Inhibition of DNA binding by differential sumoylation of heat shock factors. Mol. Cell. Biol. 26:955–64
    [Google Scholar]
58. 58. 

    Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323:1063–66
    [Google Scholar]
59. 59. 

    Mahat DB, Salamanca HH, Duarte FM, Danko CG, Lis JT 2016. Mammalian heat shock response and mechanisms underlying its genome-wide transcriptional regulation. Mol. Cell 62:63–78
    [Google Scholar]
60. 60. 

    Zuo JR, Baler R, Dahl G, Voellmy R 1994. Activation of the DNA-binding ability of human heat-shock transcription factor 1 may involve the transition from an intramolecular to an intermolecular triple-stranded coiled-coil structure. Mol. Cell. Biol. 14:7557–68
    [Google Scholar]
61. 61. 

    Voellmy R. 2005. Dominant-positive and dominant-negative heat shock factors. Methods 35:199–207
    [Google Scholar]
62. 62. 

    Salamanca HH, Antonyak MA, Cerione RA, Shi H, Lis JT 2014. Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamer. PLOS ONE 9:e96330
    [Google Scholar]
63. 63. 

    Ran X, Burchfiel ET, Dong B, Rettko NJ, Dunyak BM et al. 2018. Rational design and screening of peptide-based inhibitors of heat shock factor 1 (HSF1). Bioorg. Med. Chem. 26:5299–306
    [Google Scholar]
64. 64. 

    Santagata S, Mendillo ML, Tang YC, Subramanian A, Perley CC et al. 2013. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 341:1238303
    [Google Scholar]
65. 65. 

    Yoon YJ, Kim JA, Shin KD, Shin DS, Han YM et al. 2011. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J. Biol. Chem. 286:1737–47
    [Google Scholar]
66. 66. 

    Bach M, Lehmann A, Brünnert D, Vanselow JT, Hartung A et al. 2017. Ugi reaction-derived α-acyl aminocarboxamides bind to phosphatidylinositol 3-kinase-related kinases, inhibit HSF1-dependent heat shock response, and induce apoptosis in multiple myeloma cells. J. Med. Chem. 60:4147–60
    [Google Scholar]
67. 67. 

    Cheeseman MD, Chessum NEA, Rye CS, Pasqua AE, Tucker MJ et al. 2017. Discovery of a chemical probe bisamide (CCT251236): an orally bioavailable efficacious pirin ligand from a heat shock transcription factor 1 (HSF1) phenotypic screen. J. Med. Chem. 60:180–201
    [Google Scholar]
68. 68. 

    Rye CS, Chessum NEA, Lamont S, Pike KG, Faulder P et al. 2016. Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. Med. Chem. Commun. 7:1580–86
    [Google Scholar]
69. 69. 

    Vilaboa N, Boré A, Martin-Saavedra F, Bayford M, Winfield N et al. 2017. New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival. Nucleic Acids Res 45:5797–817
    [Google Scholar]
70. 70. 

    Neef DW, Turski ML, Thiele DJ 2010. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLOS Biol 8:e1000291
    [Google Scholar]
71. 71. 

    Calamini B, Silva MC, Madoux F, Hutt DM, Khanna S et al. 2011. Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 8:185–96
    [Google Scholar]
72. 72. 

    Westerheide SD, Bosman JD, Mbadugha BNA, Kawahara TLA, Matsumoto G et al. 2004. Celastrols as inducers of the heat shock response and cytoprotection. J. Biol. Chem. 279:56053–60
    [Google Scholar]
73. 73. 

    Moore CL, Dewal MB, Nekongo EE, Santiago S, Lu NB et al. 2016. Transportable, chemical genetic methodology for the small molecule-mediated inhibition of heat shock factor 1. ACS Chem. Biol. 11:200–10
    [Google Scholar]
74. 74. 

    Liebelt F, Sebastian RM, Moore CL, Mulder MPC, Ovaa H et al. 2019. SUMOylation and the HSF1-regulated chaperone network converge to promote proteostasis in response to heat shock. Cell Rep 26:236–49
    [Google Scholar]
75. 75. 

    Shoulders MD, Ryno LM, Cooley CB, Kelly JW, Wiseman RL 2013. Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. J. Am. Chem. Soc. 135:8129–32
    [Google Scholar]
76. 76. 

    Wong MY, DiChiara AS, Suen PH, Chen K, Doan ND, Shoulders MD 2018. Adapting secretory proteostasis and function through the unfolded protein response. Curr. Top. Microbiol. Immunol. 414:1–25
    [Google Scholar]
77. 77. 

    Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D 2000. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2:326–32
    [Google Scholar]
78. 78. 

    Nadanaka S, Okada T, Yoshida H, Mori K 2007. Role of disulfide bridges formed in the luminal domain of ATF6 in sensing endoplasmic reticulum stress. Mol. Cell. Biol. 27:1027–43
    [Google Scholar]
79. 79. 

    Gardner BM, Walter P. 2011. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. Science 333:1891–94
    [Google Scholar]
80. 80. 

    Harding HP, Zhang Y, Ron D 1999. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271–74
    [Google Scholar]
81. 81. 

    Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM 2016. The integrated stress response. EMBO Rep 17:1374–95
    [Google Scholar]
82. 82. 

    Calfon M, Zeng H, Urano F, Till JH, Hubbard SR et al. 2002. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415:92–96
    [Google Scholar]
83. 83. 

    Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS 2009. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J. Cell Biol. 186:323–31
    [Google Scholar]
84. 84. 

    Haze K, Yoshida H, Yanagi H, Yura T, Mori K 1999. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol. Biol. Cell 10:3787–99
    [Google Scholar]
85. 85. 

    Shoulders MD, Ryno LM, Genereux JC, Moresco JJ, Tu PG et al. 2013. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep 3:1279–92
    [Google Scholar]
86. 86. 

    Blackwood EA, Azizi K, Thuerauf DJ, Paxman RJ, Plate L et al. 2019. Pharmacologic ATF6 activation confers global protection in widespread disease models by reprograming cellular proteostasis. Nat. Commun. 10:187
    [Google Scholar]
87. 87. 

    Axten JM, Romeril SP, Shu A, Ralph J, Medina JR et al. 2013. Discovery of GSK2656157: an optimized PERK inhibitor selected for preclinical development. ACS Med. Chem. Lett. 4:964–68
    [Google Scholar]
88. 88. 

    Lu PD, Harding HP, Ron D 2004. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J. Cell Biol. 167:27–33
    [Google Scholar]
89. 89. 

    Das I, Krzyzosiak A, Schneider K, Wrabetz L, D'Antonio M et al. 2015. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 348:239–42
    [Google Scholar]
90. 90. 

    Krzyzosiak A, Sigurdardottir A, Luh L, Carrara M, Das I et al. 2018. Target-based discovery of an inhibitor of the regulatory phosphatase PPP1R15B. Cell 174:1216–28
    [Google Scholar]
91. 91. 

    Crespillo-Casado A, Chambers JE, Fischer PM, Marciniak SJ, Ron D 2017. PPP1R15A-mediated dephosphorylation of eIF2α is unaffected by Sephin1 or Guanabenz. eLife 6:e26109
    [Google Scholar]
92. 92. 

    Sidrauski C, Tsai JC, Kampmann M, Hearn BR, Vedantham P et al. 2015. Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response. eLife 4:e07314
    [Google Scholar]
93. 93. 

    Plate L, Cooley CB, Chen JJ, Paxman RJ, Gallagher CM et al. 2016. Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. eLife 5:e15550
    [Google Scholar]
94. 94. 

    Paxman R, Plate L, Blackwood EA, Glembotski C, Powers ET et al. 2018. Pharmacologic ATF6 activating compounds are metabolically activated to selectively modify endoplasmic reticulum proteins. eLife 7:e37168
    [Google Scholar]
95. 95. 

    Gallagher CM, Garri C, Cain EL, Ang KKH, Wilson CG et al. 2016. Ceapins are a new class of unfolded protein response inhibitors, selectively targeting the ATF6α branch. eLife 5:e11878
    [Google Scholar]
96. 96. 

    Torres SE, Gallagher CM, Plate L, Gupta M, Liem CR et al. 2019. Ceapins block the unfolded protein response sensor ATF6α by inducing a neomorphic inter-organelle tether. eLife 8:e46595
    [Google Scholar]
97. 97. 

    Cross BCS, Bond PJ, Sadowski PG, Jha BK, Zak J et al. 2012. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. PNAS 109:E869–78
    [Google Scholar]
98. 98. 

    Logue SE, McGrath EP, Cleary P, Greene S, Mnich K et al. 2018. Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. Nat. Commun. 9:e3267
    [Google Scholar]
99. 99. 

    Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S et al. 2011. Identification of an Ire1α endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 117:1311–14
    [Google Scholar]
100. 100. 

     Wang L, Perera BGK, Hari SB, Bhhatarai B, Backes BJ et al. 2012. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat. Chem. Biol. 8:982–89
     [Google Scholar]
101. 101. 

     Lin JH, Li H, Yasumura D, Cohen HR, Zhang C et al. 2007. IRE1 signaling affects cell fate during the unfolded protein response. Science 318:944–49
     [Google Scholar]
102. 102. 

     Wong MY, Chen K, Antonopoulos A, Kasper BT, Dewal MB et al. 2018. XBP1s activation can globally remodel N-glycan structure distribution patterns. PNAS 115:E10089–98
     [Google Scholar]
103. 103. 

     Dewal MB, DiChiara AS, Antonopoulos A, Taylor RJ, Harmon CJ et al. 2015. XBP1s links the unfolded protein response to the molecular architecture of mature N-glycans. Chem. Biol. 22:1301–12
     [Google Scholar]
104. 104. 

     Lee AH, Iwakoshi NN, Glimcher LH 2003. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol. Cell. Biol. 23:7448–59
     [Google Scholar]
105. 105. 

     Ying W, Du Z, Sun L, Foley KP, Proia DA et al. 2012. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol. Cancer Ther. 11:475–84
     [Google Scholar]
106. 106. 

     Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM 1994. Inhibition of heat shock protein HSP90-pp60^v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. PNAS 91:8324–28
     [Google Scholar]
107. 107. 

     Ernst JT, Neubert T, Liu M, Sperry S, Zuccola H et al. 2014. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease. J. Med. Chem. 57:3382–400
     [Google Scholar]
108. 108. 

     Patel PD, Yan P, Seidler PM, Patel HJ, Sun W et al. 2013. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2. Nat. Chem. Biol. 9:677–84
     [Google Scholar]
109. 109. 

     Lee C, Park HK, Jeong H, Lim J, Lee AJ et al. 2015. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. J. Am. Chem. Soc. 137:4358–67
     [Google Scholar]
110. 110. 

     Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ et al. 2018. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. Nat. Commun. 9:425
     [Google Scholar]
111. 111. 

     Wong MY, Doan ND, DiChiara AS, Papa LJ III, Cheah JH et al. 2018. A high-throughput assay for collagen secretion suggests an unanticipated role for Hsp90 in collagen production. Biochemistry 57:2814–27
     [Google Scholar]
112. 112. 

     Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C et al. 2018. Exploration of benzothiazole rhodacyanines as allosteric inhibitors of protein–protein interactions with heat shock protein 70 (Hsp70). J. Med. Chem. 61:6163–77
     [Google Scholar]
113. 113. 

     Fewell SW, Smith CM, Lyon MA, Dumitrescu TP, Wipf P et al. 2004. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity. J. Biol. Chem. 279:51131–40
     [Google Scholar]
114. 114. 

     Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ et al. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:93–96
     [Google Scholar]
115. 115. 

     Nillegoda NB, Kirstein J, Szlachcic A, Berynskyy M, Stank A et al. 2015. Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524:247–51
     [Google Scholar]
116. 116. 

     Stiegler SC, Rübbelke M, Korotkov VS, Weiwad M, John C et al. 2017. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex. J. Biol. Chem. 292:17073–83
     [Google Scholar]
117. 117. 

     Taylor IR, Dunyak BM, Komiyama T, Shao H, Ran X et al. 2018. High-throughput screen for inhibitors of protein-protein interactions in a reconstituted heat shock protein 70 (Hsp70) complex. J. Biol. Chem. 293:4014–25
     [Google Scholar]
118. 118. 

     Manasanch EE, Orlowski RZ. 2017. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14:417–33
     [Google Scholar]
119. 119. 

     Rock KL, Gramm C, Rothstein L, Clark K, Stein R et al. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761–71
     [Google Scholar]
120. 120. 

     Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV et al. 2005. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7:547–59
     [Google Scholar]
121. 121. 

     Mizushima N, Yoshimori T, Levine B 2010. Methods in mammalian autophagy research. Cell 140:313–26
     [Google Scholar]
122. 122. 

     Wu YT, Tan HL, Shui G, Bauvy C, Huang Q et al. 2010. Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J. Biol. Chem. 285:10850–61
     [Google Scholar]
123. 123. 

     Blommaart EFC, Krause U, Schellens JPM, Vreeling-Sindelárová H, Meijer AJ 1997. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur. J. Biochem. 243:240–46
     [Google Scholar]
124. 124. 

     Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y 1991. Bafilomycin-A1, a specific inhibitor of vacuolar-type H⁺-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J. Biol. Chem. 266:17707–12
     [Google Scholar]
125. 125. 

     Chou TF, Brown SJ, Minond D, Nordin BE, Li K et al. 2011. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. PNAS 108:4834–39
     [Google Scholar]
126. 126. 

     Magnaghi P, D'Alessio R, Valsasina B, Avanzi N, Rizzi S et al. 2013. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9:548–56
     [Google Scholar]
127. 127. 

     Savitski MM, Zinn N, Faelth-Savitski M, Poeckel D, Gade S et al. 2018. Multiplexed proteome dynamics profiling reveals mechanisms controlling protein homeostasis. Cell 173:260–74
     [Google Scholar]
128. 128. 

     Mizukami S, Watanabe S, Akimoto Y, Kikuchi K 2012. No-wash protein labeling with designed fluorogenic probes and application to real-time pulse-chase analysis. J. Am. Chem. Soc. 134:1623–29
     [Google Scholar]
129. 129. 

     Bojkowska K, Santoni de Sio F, Barde I, Offner S, Verp S et al. 2011. Measuring in vivo protein half-life. Chem. Biol. 18:805–15
     [Google Scholar]
130. 130. 

     Fuchs J, Böhme S, Oswald F, Hedde PN, Krause M et al. 2010. A photoactivatable marker protein for pulse-chase imaging with superresolution. Nat. Methods 7:627–30
     [Google Scholar]
131. 131. 

     Barry JD, Donà E, Gilmour D, Huber W 2016. TimerQuant: a modelling approach to tandem fluorescent timer design and data interpretation for measuring protein turnover in embryos. Development 143:174–79
     [Google Scholar]
132. 132. 

     Khmelinskii A, Keller PJ, Bartosik A, Meurer M, Barry JD et al. 2012. Tandem fluorescent protein timers for in vivo analysis of protein dynamics. Nat. Biotechnol. 30:708–14
     [Google Scholar]
133. 133. 

     Leuenberger P, Ganscha S, Kahraman A, Cappelletti V, Boersema PJ et al. 2017. Cell-wide analysis of protein thermal unfolding reveals determinants of thermostability. Science 355:eaai7825
     [Google Scholar]
134. 134. 

     Chen MZ, Moily NS, Bridgford JL, Wood RJ, Radwan M et al. 2017. A thiol probe for measuring unfolded protein load and proteostasis in cells. Nat. Commun. 8:474
     [Google Scholar]
135. 135. 

     LeVine H III 1993. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2:404–10
     [Google Scholar]
136. 136. 

     Ramdzan YM, Polling S, Chia CPZ, Ng IHW, Ormsby AR et al. 2012. Tracking protein aggregation and mislocalization in cells with flow cytometry. Nat. Methods 9:467–70
     [Google Scholar]
137. 137. 

     Jung KH, Kim SF, Liu Y, Zhang X 2019. A fluorogenic AggTag method based on Halo- and SNAP-tags to simultaneously detect aggregation of two proteins in live cells. ChemBioChem 20:1078–87
     [Google Scholar]
138. 138. 

     Roberti MJ, Jovin TM, Jares-Erijman E 2011. Confocal fluorescence anisotropy and FRAP imaging of α-synuclein amyloid aggregates in living cells. PLOS ONE 6:e23338
     [Google Scholar]
139. 139. 

     Esbjörner EK, Chan F, Rees E, Erdelyi M, Luheshi LM et al. 2014. Direct observations of amyloid β self-assembly in live cells provide insights into differences in the kinetics of Aβ(1–40) and Aβ(1–42) aggregation. Chem. Biol. 21:732–42
     [Google Scholar]
140. 140. 

     Savitski MM, Reinhard FBM, Franken H, Werner T, Savitski MF et al. 2014. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346:eaai1255784
     [Google Scholar]
141. 141. 

     Drake WR, Hou CW, Zachara NE, Grimes CL 2018. New use for CETSA: monitoring innate immune receptor stability via post-translational modification by OGT. J. Bioenerg. Biomembr. 50:231–40
     [Google Scholar]
142. 142. 

     Freilich R, Arhar T, Abrams JL, Gestwicki JE 2018. Protein–protein interactions in the molecular chaperone network. Acc. Chem. Res. 51:940–49
     [Google Scholar]
143. 143. 

     Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M et al. 2015. ΔF508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature 528:510–16
     [Google Scholar]
144. 144. 

     Branon TC, Bosch JA, Sanchez AD, Udeshi ND, Svinkina T et al. 2018. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36:880–87
     [Google Scholar]
145. 145. 

     Hong F, Rachidi SM, Lundgren D, Han D, Huang X et al. 2017. Mapping the interactome of a major mammalian endoplasmic reticulum heat shock protein 90. PLOS ONE 12:e0169260
     [Google Scholar]
146. 146. 

     Markmiller S, Soltanieh S, Server KL, Mak R, Jin W et al. 2018. Context-dependent and disease-specific diversity in protein interactions within stress granules. Cell 172:590–604
     [Google Scholar]
147. 147. 

     Lobingier BT, Hüttenhain R, Eichel K, Miller KB, Ting AY et al. 2017. An approach to spatiotemporally resolve protein interaction networks in living cells. Cell 169:350–60
     [Google Scholar]
148. 148. 

     Jia S, Peng J, Gao B, Chen Z, Zhou Y et al. 2011. Relative quantification of protein-protein interactions using a dual luciferase reporter pull-down assay system. PLOS ONE 6:e26414
     [Google Scholar]
149. 149. 

     Petrakis S, Raskó T, Russ J, Friedrich RP, Stroedicke M et al. 2012. Identification of human proteins that modify misfolding and proteotoxicity of pathogenic ataxin-1. PLOS Genet 8:e1002897
     [Google Scholar]
150. 150. 

     Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD et al. 2012. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150:987–1001
     [Google Scholar]
151. 151. 

     Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78:959–91
     [Google Scholar]